Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: A comparison of patients treated with sulfonylureas and metformin

Diabetologia

Volumn 49, Issue 5, 2006, Pages 930-936

  Evans, J M M ^a   Ogston, S A ^a   Emslie Smith, A ^b   Morris, A D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Mill Practice ^*  (United Kingdom)

Author keywords

Cardiovascular risk; Metformin; Sulfonylureas

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; FEMALE; GENDER; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INFORMATION SYSTEM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; UNITED KINGDOM;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND; SULFONYLUREA COMPOUNDS; SURVIVAL ANALYSIS;

EID: 33646422782     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0176-9     Document Type: Article

References (16)

1. Johnson JA, Simpson SH, Majumdar SR, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248
2. Seltzer HS (1972) A summary of criticisms of the findings of the University Group Diabetes Program. Diabetes 21:976-979
3. Leibowitz G, Cerasi E (1996) Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 39:503-514
4. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
5. Nathan DM (1998) Some answers, more controversy, from UKPDS. Lancet 352:832-833
6. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
7. Olsson J, Lindberg G, Gottsater M et al (2000) Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558-560
8. Fisman EZ, Tenenbaum A, Boyko V et al (2001) Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7 year follow-up. Clin Cardiol 24:151-158
9. Gulliford M, Latinovic R (2004) Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239-245
10. Evans JMM, McDevitt DG, MacDonald TM (1995) The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharm Med 9:177-184
11. Morris AD, Boyle DIR, MacAlpine R et al, for the DARTS/ MEMO Collaboration (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record-linkage to create a diabetes register. Br Med J 315:524-528
12. World Health Organization (1978) Manual of the international statistical classification of diseases, injuries and causes of death. Ninth revision. World Health Organization, Geneva
13. World Health Organization (1994) International statistical classification of diseases and related health problems. Tenth revision. World Health Organization, Geneva
14. Carstairs V (1990) Deprivation and health in Scotland. Health Bull (Edinb) 48:162-175
15. Sasali A, Leahy JL (2003) Is metformin cardioprotective? Diabetes Care 26:243-244
16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction. New Engl J Med 339:229-234